Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction-Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial.
Sign Up to like & getrecommendations! Published in 2020 at "American heart journal"
DOI: 10.1016/j.ahj.2020.01.012
Abstract: BACKGROUND Adverse cardiac remodeling is a major risk factor for the development of post myocardial infarction (MI) heart failure (HF). This study investigates the effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after… read more here.
Keywords: adverse cardiac; chymase inhibitor; cardiac remodeling; infarction ... See more keywords
ASB17061, a novel chymase inhibitor, prevented the development of angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice.
Sign Up to like & getrecommendations! Published in 2019 at "European journal of pharmacology"
DOI: 10.1016/j.ejphar.2019.05.032
Abstract: Our aim was to examine the effects of ASB17061, an orally active novel chymase inhibitor, on angiotensin II-induced abdominal aortic aneurysm (AAA) in apolipoprotein E-deficient mice. Oral administration of ASB17061 (10 mg/kg) significantly suppressed angiotensin II-induced… read more here.
Keywords: chymase; novel chymase; angiotensin induced; induced abdominal ... See more keywords